MN SF100

Permits terminally ill patients to use investigational drugs, biological products, or devices that have completed Phase 1 clinical trials but lack FDA approval, provided they receive written physician recommendation and informed consent.

Requires eligible patients to have a terminal illness, consider all available FDA-approved treatment options, obtain physician prescription or recommendation, and provide written informed consent (or parental/guardian consent if under 18 or mentally incapacitated).

Makes manufacturer provision of investigational treatments optional and allows manufacturers to either provide treatments free or require patients to pay manufacturing costs.

Protects health care providers from civil penalties or disciplinary action by professional licensing boards for prescribing or treating eligible patients under this section, and shields providers from liability for patient harm resulting from investigational treatments.

Specifies that medical assistance and early periodic screening, diagnosis, and treatment (EPSDT) programs do not cover costs associated with investigational drugs, biological products, or devices; exception allows incarcerated persons to access treatments only with department medical director approval.